Download PDF
Int J Angiol 2014; 23(01): 011-016
DOI: 10.1055/s-0033-1363423
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Low Levels of Serum Soluble Receptors for Advanced Glycation End Products, Biomarkers for Disease State: Myth or Reality

Kailash Prasad
1   Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
17 February 2014 (online)

   Permissions and Reprints

Abstract

Advanced glycation end products (AGEs) interact with the receptor for AGEs (RAGE) on the membrane and induce deleterious effects via activation of nuclear factor kappa-B, and increased oxidative stress and inflammatory mediators. AGEs also combine with circulating soluble receptors (endogenous secretory RAGE [esRAGE] and soluble receptor for RAGE [sRAGE]) and sequester RAGE ligands and act as a cytoprotective agent. esRAGE is secreted from the cells and is a spliced variant of RAGE. The sRAGE on the other hand is proteolytically cleaved from cell surface receptor via matrix metalloproteinase (MMPs). sRAGE is elevated in type 1 and type 2 diabetes and in patients with decreased renal function. Serum levels of sRAGE are reduced in diseases including coronary artery disease, atherosclerosis, essential hypertension, chronic obstructive lung disease, heart failure, and hypercholesterolemia. Serum levels of AGEs are elevated in patients with coronary artery disease and atherosclerosis. However, the increases in serum AGEs are very high in patients with diabetes and renal disease. There is a positive correlation between serum levels of AGEs and RAGE and sRAGE. The elevated levels of sRAGE in patients with diabetes and impaired renal function may be due to increased levels of MMPs. AGEs increase in the expression and production of MMPs, which would increase the cleavage of sRAGE from cell surface. In conclusion, low level of serum sRAGE is a good biomarker for disease other than diabetes and renal disease. A unified formula that takes into consideration of AGEs, sRAGE, and esRAGE such as AGE/sRAGE or AGEs/esRAGE would be better biomarker than sRAGE or esRAGE for all AGE-RAGE–associated diseases including diabetes and renal disease.

Keywords

advanced glycation end products - soluble receptor for AGEs - endogenous secretory receptor for AGEs - biomarker - coronary artery disease - diabetes - renal dysfunction - unified biomarker for AGE-RAGE–associated diseases
 

  • References

  • 1 Takeuchi M, Yanase Y, Matsuura N , et al. Immunological detection of a novel advanced glycation end-product. Mol Med 2001; 7 (11) 783-791
    PubMedGoogle Scholar
  • 2 Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003; 25 (3–4) 275-281
    CrossrefPubMedGoogle Scholar
  • 3 Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37 (3) 586-600
    CrossrefPubMedGoogle Scholar
  • 4 Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006; 15: 57-68
    PubMedGoogle Scholar
  • 5 Neeper M, Schmidt AM, Brett J , et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267 (21) 14998-15004
    PubMedGoogle Scholar
  • 6 Wendt T, Tanji N, Guo J , et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14 (5) 1383-1395
    CrossrefPubMedGoogle Scholar
  • 7 Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84 (5) 489-497
    CrossrefPubMedGoogle Scholar
  • 8 Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498 (2–3) 99-111
    CrossrefPubMedGoogle Scholar
  • 9 Tam XHL, Shiu SWM, Leng L, Bucala R, Betteridge DJ, Tan KCB. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011; 120 (2) 81-89
    CrossrefPubMedGoogle Scholar
  • 10 Koyama H, Shoji T, Yokoyama H , et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2587-2593
    CrossrefPubMedGoogle Scholar
  • 11 Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13 (17) 1971-1978
    CrossrefPubMedGoogle Scholar
  • 12 Colhoun HM, Betteridge DJ, Durrington P , et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011; 60 (9) 2379-2385
    CrossrefPubMedGoogle Scholar
  • 13 Fujisawa K, Katakami N, Kaneto H , et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013; 227 (2) 425-428
    CrossrefPubMedGoogle Scholar
  • 14 Tan KCB, Shiu SWM, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49 (11) 2756-2762
    CrossrefPubMedGoogle Scholar
  • 15 Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 2005; 51 (9) 1749-1750
    CrossrefPubMedGoogle Scholar
  • 16 Nin JW, Jorsal A, Ferreira I , et al. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 2010; 59 (8) 2027-2032
    CrossrefPubMedGoogle Scholar
  • 17 Katakami N, Matsuhisa M, Kaneto H , et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005; 28 (11) 2716-2721
    CrossrefPubMedGoogle Scholar
  • 18 Kalousová M, Hodková M, Kazderová M , et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47 (3) 406-411
    CrossrefPubMedGoogle Scholar
  • 19 Basta G, Leonardis D, Mallamaci F , et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010; 77 (3) 225-231
    CrossrefPubMedGoogle Scholar
  • 20 Nin JWM, Ferreira I, Schalkwijk CG , et al; EURODIAB Prospective Complications Study Group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009; 52 (4) 705-714
    CrossrefPubMedGoogle Scholar
  • 21 Hammady MMR, Khashali SEL, Halim HA, Rashed L, Hussein M. Soluble receptor for advanced glycation end products (sRAGE) in non-diabetic hemodialysis patients and chronic kidney disease. Med J Cairo Univ 2012; 80: 69-75
    PubMedGoogle Scholar
  • 22 Falcone C, Emanuele E, D'Angelo A , et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25 (5) 1032-1037
    CrossrefPubMedGoogle Scholar
  • 23 Lindsey JB, de Lemos JA, Cipollone F , et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009; 32 (7) 1218-1220
    CrossrefPubMedGoogle Scholar
  • 24 Hudson BI, Moon YP, Kalea AZ , et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 2011; 216 (1) 192-198
    CrossrefPubMedGoogle Scholar
  • 25 Selvin EM, Halushka MK, Rawlings AM , et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013; 62 (6) 2116-2121
    CrossrefPubMedGoogle Scholar
  • 26 McNair ED, Wells CR, Qureshi AM , et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol 2009; 18 (4) 187-192
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 McNair ED, Wells CR, Mabood Qureshi A , et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010; 33 (11) 678-685
    CrossrefPubMedGoogle Scholar
  • 28 Santilli F, Bucciarelli L, Noto D , et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007; 43 (9) 1255-1262
    CrossrefPubMedGoogle Scholar
  • 29 Geroldi D, Falcone C, Emanuele E , et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23 (9) 1725-1729
    CrossrefPubMedGoogle Scholar
  • 30 Emanuele E, D'Angelo A, Tomaino C , et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005; 62 (11) 1734-1736
    CrossrefPubMedGoogle Scholar
  • 31 Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011; 12: 37-45
    CrossrefPubMedGoogle Scholar
  • 32 Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011; 37 (3) 516-522
    CrossrefPubMedGoogle Scholar
  • 33 Wang LJ, Lu L, Zhang FR, Chen QJ, De Caterina R, Shen WF. Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail 2011; 13 (4) 440-449
    CrossrefPubMedGoogle Scholar
  • 34 Basta G, Berti S, Cocci F , et al. Plasma N-epsilon-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis 2008; 19 (5) 299-305
    CrossrefPubMedGoogle Scholar
  • 35 Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006; 70 (1) 218-224
    CrossrefPubMedGoogle Scholar
  • 36 Tan KCB, Chow WS, Tam S, Bucala R, Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004; 27 (1) 223-228
    CrossrefPubMedGoogle Scholar
  • 37 Berg TJ, Dahl-Jørgensen K, Torjesen PA, Hanssen KF. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care 1997; 20 (6) 1006-1008
    CrossrefPubMedGoogle Scholar
  • 38 Berg TJ, Clausen JT, Torjesen PA, Dahl-Jørgensen K, Bangstad HJ, Hanssen KF. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1998; 21 (11) 1997-2002
    CrossrefPubMedGoogle Scholar
  • 39 Sharp PS, Rainbow S, Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med 2003; 20 (7) 575-579
    CrossrefPubMedGoogle Scholar
  • 40 Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22 (9) 1543-1548
    CrossrefPubMedGoogle Scholar
  • 41 Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001; 24 (9) 1620-1623
    CrossrefPubMedGoogle Scholar
  • 42 Selvaraj N, Bobby Z, Das AK, Ramesh R, Koner BC. An evaluation of level of oxidative stress and protein glycation in nondiabetic undialyzed chronic renal failure patients. Clin Chim Acta 2002; 324 (1–2) 45-50
    CrossrefPubMedGoogle Scholar
  • 43 Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000; 49 (8) 1030-1035
    CrossrefPubMedGoogle Scholar
  • 44 Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 2000; 35 (3) 365-380
    CrossrefPubMedGoogle Scholar
  • 45 Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46 (1) 216-222
    CrossrefPubMedGoogle Scholar
  • 46 Makita Z, Radoff S, Rayfield EJ , et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325 (12) 836-842
    CrossrefPubMedGoogle Scholar
  • 47 Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int 1999; 55 (2) 389-399
    CrossrefPubMedGoogle Scholar
  • 48 Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000; 2 (5) 430-436
    CrossrefPubMedGoogle Scholar
  • 49 Beirhaus A, Schiekofer S, Schwaninger M , et al. P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50(2): 2792-2808
    CrossrefPubMedGoogle Scholar
  • 50 Zhang WR, Hou FF, Liu SX , et al. Advanced glycation end products accelerate atherosclerosis via enhancement of oxidative stress [in Chinese]. Zhonghua Yi Xue Za Zhi 2004; 84 (13) 1066-1072
    PubMedGoogle Scholar
  • 51 Ritthaler U, Deng Y, Zhang Y , et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995; 146 (3) 688-694
    PubMedGoogle Scholar
  • 52 Soulis T, Thallas V, Youssef S , et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40 (6) 619-628
    CrossrefPubMedGoogle Scholar
  • 53 Miura J, Yamamoto Y, Osawa M , et al. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 2007; 27 (1) 253-254
    CrossrefPubMedGoogle Scholar
  • 54 Stitt AW, He C, Friedman S , et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med 1997; 3 (9) 617-627
    PubMedGoogle Scholar
  • 55 Yamagishi S, Adachi H, Nakamura K , et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006; 55 (9) 1227-1231
    CrossrefPubMedGoogle Scholar
  • 56 Yonekura H, Yamamoto Y, Sakurai S , et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370 (Pt 3) 1097-1109
    CrossrefPubMedGoogle Scholar
  • 57 Zhang F, Kent KC, Yamanouchi D , et al. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg 2009; 250 (3) 416-423
    PubMedGoogle Scholar
  • 58 Zhang F, Banker G, Liu X , et al. The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res 2011; 171 (2) 871-876
    CrossrefPubMedGoogle Scholar
  • 59 Rasheed Z, Anbazhagan AN, Akhtar N, Ramamurthy S, Voss FR, Haqqi TM. Green tea polyphenol epigallocatechin-3–gallate inhibits advanced glycation end products- induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther 2009; 11: R71
    CrossrefPubMedGoogle Scholar
  • 60 Nah SS, Choi IY, Yoo B, Kim YG, Moon HB, Lee CK. Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-α in human osteoarthritic chondrocytes. FEBS Lett 2007; 581 (9) 1928-1932
    CrossrefPubMedGoogle Scholar
  • 61 Dai R, Wang L, Jim H, Sun Z. Effects of advanced glycation end products on expression of EMMPRIN and MMP-2 in moue osteoblast. African J Pharmac Pharmacol. 2010; 4: 453-464
    PubMedGoogle Scholar
  • 62 Uemura S, Matsushita H, Li W , et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001; 88 (12) 1291-1298
    CrossrefPubMedGoogle Scholar
  • 63 Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiedemann P. Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol 2002; 240 (12) 996-1002
    CrossrefPubMedGoogle Scholar
  • 64 Zhu P, Ren M, Yang C, Hu YX, Ran JM, Yan L. Involvement of RAGE, MAPK and NF-κB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol 2012; 21 (2) 123-129
    CrossrefPubMedGoogle Scholar
  • 65 Zhang F, Banker G, Liu X , et al. The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res 2011; 171 (2) 871-876
    CrossrefPubMedGoogle Scholar
  • 66 Song W, Ergul A. Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol 2006; 5: 3
    CrossrefPubMedGoogle Scholar
  • 67 Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98 (11) 2572-2579
    CrossrefPubMedGoogle Scholar
  • 68 Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280 (1) C53-C60
    PubMedGoogle Scholar
  • 69 Koyama H, Yamamoto H, Nishizawa Y. Endogenous secretory RAGE as a novel biomarker for metabolic syndrome and cardiovascular diseases. Biomark Insights 2007; 2: 331-339
    PubMedGoogle Scholar